Royce & Associates’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$51.7M	Buy	2,089,906 +179,139	+9%	+$4.27M	0.51%	33
2025 Q4	$44.6M	Sell	1,910,767 -124,198	-6%	-$2.77M	0.45%	41
2025 Q3	$40.1M	Buy	2,034,965 +452,103	+29%	+$9.3M	0.4%	60
2025 Q2	$34.3M	Sell	1,582,862 -15,498	-1%	-$366K	0.35%	73
2025 Q1	$38.8M	Sell	1,598,360 -265,991	-14%	-$5.99M	0.42%	58
2024 Q4	$38.9M	Sell	1,864,351 -156,754	-8%	-$3.37M	0.36%	65
2024 Q3	$40.2M	Sell	2,021,105 -140,917	-7%	-$2.61M	0.37%	74
2024 Q2	$33.5M	Buy	2,162,022 +78,009	+4%	+$1.21M	0.31%	85
2024 Q1	$33.2M	Buy	2,084,013 +340,939	+20%	+$5.14M	0.3%	95
2023 Q4	$29.3M	Buy	1,743,074 +131,372	+8%	+$1.8M	0.27%	98
2023 Q3	$18.8M	Buy	1,611,702 +571,714	+55%	+$7.65M	0.19%	149
2023 Q2	$14M	Buy	1,039,988 +424,020	+69%	+$6.1M	0.14%	209
2023 Q1	$10.2M	Buy	615,968 +84,079	+16%	+$1.39M	0.1%	303
2022 Q4	$9.89M	Sell	531,889 -126,658	-19%	-$1.95M	0.1%	295
2022 Q3	$8.45M	Sell	658,547 -1,441,678	-69%	-$17.1M	0.1%	309
2022 Q2	$14.7M	Sell	2,100,225 -161,682	-7%	-$1.19M	0.15%	186
2022 Q1	$18.8M	Sell	2,261,907 -321,961	-12%	-$2.28M	0.16%	174
2021 Q4	$17.5M	Sell	2,583,868 -423,126	-14%	-$2.78M	0.13%	236
2021 Q3	$15.9M	Sell	3,006,994 -66,852	-2%	-$366K	0.12%	275
2021 Q2	$17.7M	Sell	3,073,846 -175,804	-5%	-$907K	0.12%	283
2021 Q1	$15M	Buy	3,249,650 +844,521	+35%	+$3.36M	0.1%	328
2020 Q4	$8.03M	Buy	2,405,129 +620,239	+35%	+$2.08M	0.07%	440
2020 Q3	$5.3M	Buy	1,784,890 +474,984	+36%	+$1.86M	0.06%	456
2020 Q2	$6.05M	Buy	1,309,906 +665,915	+103%	+$2.99M	0.07%	409
2020 Q1	$2.48M	Sell	643,991 -136,791	-18%	-$561K	0.03%	543
2019 Q4	$2.93M	Buy	+780,782	New	+$3.65M	0.03%	617